Belgium’s ExeVir raises €25M from EIB to develop novel COVID-19 therapeutic
ExeVir Bio is a clinical stage biotechnology company developing nanobody based therapeutics focusing on infectious diseases.
ExeVir Bio is a clinical stage biotechnology company developing nanobody based therapeutics focusing on infectious diseases.
The COVID-19 pandemic brought numerous challenges for companies, creating radically different settings to operate. Businesses, both small and large globally, ...
At the TNW Conference 2021, the predominant theme was the "sense of normalcy". After being forced to delay last year's ...
Barcelona-based Seqera Labs has announced that it raised $5.5M(€4.6M) in a seed funding round
Vaccines and antibiotics continue to revolutionise our ability to prevent diseases, improve health and save lives. According to WHO (World ...
Vaccitech is a clinical-stage biopharmaceutical company that is engaged in the discovery and development of two viral vector vaccines, one ...
While COVID-19 vaccination has started, gradual lifting of lockdown measures will still take some time. Even then, close monitoring of ...
Wingcopter will use the funds to strengthen its leadership position in drone-based logistics, with a special focus on healthcare-related applications, ...
At present, the workplace revolution is driven by digital workplace transformation and supported by various technology services. Based out of ...
The aviation industry was hit hard by the pandemic with people staying at home and avoiding travel. Helping the aviation ...
Silicon Canals © 2014-2023 | Design: Bright Idiots. Images: Depositphotos
Silicon Canals © 2014-2023 | Design: Bright Idiots. Images: Depositphotos